Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
about
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study.Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetesMetabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasoundVSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.Alanine aminotransferase is associated with an adverse nocturnal blood glucose profile in individuals with normal glucose regulationIndependent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.Right ventricular function and its relationship with grade of hepatosteatosis in non-alcoholic fatty liver disease.Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.Exogenous estrogen protects mice from the consequences of obesity and alcohol.Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes riskAssociation of serum alanine aminotransferase levels with cardiometabolic risk factors in normal-weight and overweight children.Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis Beyond Metabolic Disorders in Non-Diabetic PatientsMultidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: a cross-sectional observational studySterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolismAssociation of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis.Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link?Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial.The Risk for Insulin Resistance according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men.Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey.The effects on weight loss and gene expression in adipose and hepatic tissues of very-low carbohydrate and low-fat isoenergetic diets in diet-induced obese mice.Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease.An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease.The clinical significance of pancreatic steatosis.Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis.A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells.Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans.Serum alanine aminotransferase/aspartate aminotransferase ratio is one of the best markers of insulin resistance in the Chinese population.Vague relationship between alcohol consumption and metabolic syndrome in nonobese people.Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals.Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults.Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects.Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance.Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.
P2860
Q27006992-8B0DE9EC-CBB1-4372-9C38-E3864BD450DCQ33509626-AD2D55C2-4886-4D39-B776-1471ABBDBA89Q33573424-7BC9DE16-0751-4D8F-8BCC-56F925931611Q34185998-B6A2E0A4-DE8A-41DF-82D1-3C07295E579FQ34331647-AE4CBAD0-2358-4361-A974-85DC6A54144CQ34428997-4AC9709D-EDCF-44C9-9DC3-CBF2E6E2D765Q34592729-EDFE16F0-5FE1-45AB-9252-D3F90F86421AQ34729697-E505559B-0679-4CA3-9977-7B7EBDCA65E0Q35602513-E8A86210-19C2-4C42-9043-4E42F37F4E5BQ35962132-4127DF4D-CD6E-491D-9A2C-C48747591182Q35997786-19A0BCAE-7D44-4993-8FF9-A258DA9D7D15Q36113238-F0B6B556-A66D-4F81-B922-22FA14932AC6Q36222629-2A4BA84F-7DE6-4B7E-808B-1545BD5736B5Q36244853-4ACC0874-ADDF-4B64-99D9-ABE3D55A57C3Q36399373-1D16D4B3-0C6D-4989-9444-8EF5F16CF273Q36470320-AB18A139-4AA4-4509-A733-7E9B28496066Q36546127-BEC5DAFD-311A-447F-B741-71EC0DB4EE9EQ36720511-2A07EEFA-E3A7-492A-954E-97CADA9B24BCQ36953626-7227B195-DB56-4A6D-B82A-231BA81C8354Q37205022-B95C1BDE-A9FB-497E-BD8F-ECA734D7718BQ37217292-8AA61D3E-C36F-4890-9E8B-57529A0FA672Q37305834-7E4EC976-0125-4742-9F22-7A2E82B0A82BQ37323426-29C910EE-FE19-478A-9ED0-EC13253C73A8Q37337328-C3155A55-5AC1-4806-B811-2D30F4D32191Q37400831-48B8A69A-4F6C-412A-9D6F-3C54E8E8BE83Q37615039-3CD9DDC1-904C-4537-A55C-BDD7C1D66F82Q37621344-06690380-7441-4A80-B526-6DD7E6BF25F7Q37838235-4F0BCA77-658F-4928-8423-AFE9AB0FB1CCQ38861634-E3F7454B-F4C8-4335-878F-0D767462699EQ41487313-FB17EECD-CF96-4730-AF57-A79641E4DE37Q42278845-76D9ED68-A515-4F8A-B690-2236F9E40F18Q42373541-5C2565E8-CD47-43DD-AC5B-0EA6EB6F5C00Q42430037-2AB74DD7-E6E6-40C5-9B79-23F450F63AB9Q42933187-9A27E682-AEEA-40FE-8954-5E7D85946C41Q43152304-1E884977-F1D7-41CC-A123-E4070D1CF3D4Q43628070-27583004-EE09-4150-B96A-9B428C082115Q44557222-377C2929-39E1-42BA-8F62-86C67BE076C9Q45337960-C985471D-CACC-4409-9343-4039C1229EA5Q45752530-B6BE7530-54F0-4337-94B7-A201724D376EQ45796522-181FC8C9-C3C5-4798-AC4C-65E4F19B7C11
P2860
Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@en
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@nl
type
label
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@en
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@nl
prefLabel
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@en
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@nl
P2093
P356
P1433
P1476
Should nonalcoholic fatty live ...... nonobese nondiabetic subjects.
@en
P2093
Barbara Uberti
Giampaolo Biroli
Gianfranco Pagano
Giovanni Musso
Maurizio Cassader
Roberto Gambino
P304
P356
10.2337/DC07-1526
P407
P577
2007-12-04T00:00:00Z